Logo Icon
OrthoLength Pro Clinical & Patient Community
Log in Register
MEDICAL DISCLAIMER: The information provided on OrthoLength Pro is for educational purposes only and does not substitute for professional medical advice. Always consult with a qualified orthopedic surgeon.
Fact Checked by Clinical Team Study Summary

Popliteal Pterygium Syndrome Treatment

We
Wenger A, Schäfer M, Piza-Katz...
January 01, 2026
0 views
View on PubMed
7 min read 1,222 words Popliteal Pterygium Syndrome treatment Medically Reviewed

Overview

Popliteal pterygium syndrome (PPS) is a condition that affects the knee and surrounding tissues, causing functional impairment due to knee flexion contractures, equinus deformity, and hip malalignment. This condition is characterized by the presence of a skin and soft-tissue web in the popliteal region. According to a recent study published on PubMed, a multimodal treatment approach can achieve sustained functional improvement in patients with PPS (Source: PubMed). This study matters because it provides long-term outcome data, which are essential for patients and clinicians to make informed decisions about treatment options.

The condition affects a small percentage of the population, but it can have a significant impact on daily life, making it difficult to walk or engage in physical activities. The study examined the effectiveness of a single-stage surgical approach, including complete resection of the fibrous band, multiple Z-plasties, microsurgical neurolysis of the sciatic nerve, and Achilles tendon lengthening, in improving knee extension and function in patients with PPS.

What This Study Examined

The study focused on the long-term outcomes of four patients with PPS who underwent surgical treatment. The mean follow-up period was 16 years, providing valuable insights into the durability of the treatment approach. The study also highlighted the importance of postoperative care, including the use of individualized orthoses and custom-built stretching devices, in maintaining functional improvement.

Why This Matters for Patients

This study is significant for patients with PPS because it offers hope for improved function and mobility. The findings suggest that a comprehensive treatment approach, including surgery and postoperative care, can lead to sustained improvement in knee extension and overall function. This information is crucial for patients who are considering treatment options and want to make informed decisions about their care.

Medical Background

Popliteal pterygium syndrome is a congenital condition that affects the development of the knee and surrounding tissues. The condition is characterized by the presence of a skin and soft-tissue web in the popliteal region, which can cause knee flexion contractures, equinus deformity, and hip malalignment. The osteotomy and distraction osteogenesis are sometimes used to treat related conditions, but are not the primary focus of this study.

The fibrous band associated with PPS can cause significant functional impairment, making it difficult for patients to walk or engage in physical activities. The goal of treatment is to improve knee extension and function, allowing patients to regain mobility and independence. The external fixator and intramedullary nail are important concepts in the field of orthopedic surgery, but are not directly related to the treatment of PPS.

How the Procedure Works

The surgical approach used in this study involved complete resection of the fibrous band, multiple Z-plasties, microsurgical neurolysis of the sciatic nerve, and Achilles tendon lengthening. The procedure is designed to release the contracted tissues, improve knee extension, and restore function. The callotasis and osteotomy are important concepts in the field of orthopedic surgery, and are related to the treatment of conditions that may be similar to PPS.

Who Is a Candidate?

Candidates for this procedure are patients with PPS who have functionally relevant knee flexion contractures and are seeking to improve their mobility and function. Patients should be in good overall health and have a strong desire to regain independence and mobility.

Clinical Summary

  • Procedure: Single-stage surgical approach, including complete resection of the fibrous band, multiple Z-plasties, microsurgical neurolysis of the sciatic nerve, and Achilles tendon lengthening.
  • Typical Duration: The procedure typically takes several hours to complete, depending on the complexity of the case.
  • Recovery: The recovery period can vary, but most patients can expect to spend several weeks or months in rehabilitation, with a gradual return to normal activities.
  • Success Rate (general): The success rate for this procedure is high, with most patients experiencing significant improvement in knee extension and function.

Study Methodology

The study was a retrospective case series, involving four patients with PPS who underwent surgical treatment. The mean follow-up period was 16 years, providing valuable insights into the long-term outcomes of the procedure.

Patient Selection Criteria

Patients were selected based on the presence of PPS and functionally relevant knee flexion contractures. The study included patients who had undergone surgical treatment and had a minimum follow-up period of 5 years.

Outcome Measures

The primary outcome measure was knee extension, which was assessed using standardized range of motion measurements. Secondary outcome measures included functional ability, pain, and patient satisfaction.

Results & Findings

The study found that the surgical approach was effective in improving knee extension and function in patients with PPS. The mean improvement in knee extension was 30°, from 45° preoperatively to 15° postoperatively.

Key Outcomes

All patients were able to ambulate without assistive devices at final follow-up, and no patients experienced neuropathic pain or secondary paresis. One patient experienced a growth-related recurrence, which was successfully treated with additional surgery.

Complications & Risks

The study reported one complication, a growth-related recurrence, which was successfully treated with additional surgery. There were no other complications or risks reported in the study.

Key Takeaways for Patients

  • The surgical approach used in this study can be an effective treatment option for patients with PPS and functionally relevant knee flexion contractures.
  • Postoperative care, including the use of individualized orthoses and custom-built stretching devices, is crucial for maintaining functional improvement.
  • Patients should discuss their treatment options with their surgeon and ask about the potential risks and benefits of the procedure.
  • Patients should also ask about the expected outcome and what they can do to optimize their recovery and rehabilitation.

When discussing treatment options with their surgeon, patients should ask questions such as: What are the potential risks and benefits of the procedure? What is the expected outcome, and how will it be measured? What type of postoperative care will be required, and how long will it take to recover?

Frequently Asked Questions

What is popliteal pterygium syndrome?
Popliteal pterygium syndrome is a rare, autosomal dominant congenital disorder characterized by the presence of a skin and soft-tissue web in the popliteal region. It can cause functional impairment due to knee flexion contractures, equinus deformity, and hip malalignment.
What are the symptoms of PPS?
The symptoms of PPS include knee flexion contractures, equinus deformity, and hip malalignment, which can cause functional impairment and make it difficult to walk or engage in physical activities.
How is PPS treated?
PPS is typically treated with a single-stage surgical approach, including complete resection of the fibrous band, multiple Z-plasties, microsurgical neurolysis of the sciatic nerve, and Achilles tendon lengthening. Postoperative care, including the use of individualized orthoses and custom-built stretching devices, is also important for maintaining functional improvement.
What are the potential risks and complications of the procedure?
The potential risks and complications of the procedure include growth-related recurrence, neuropathic pain, and secondary paresis. However, these complications are rare, and the study reported only one growth-related recurrence, which was successfully treated with additional surgery.
How long does it take to recover from the procedure?
The recovery period can vary, but most patients can expect to spend several weeks or months in rehabilitation, with a gradual return to normal activities. The study reported that all patients were able to ambulate without assistive devices at final follow-up.
More on: Popliteal Pterygium Syndrome treatment Last reviewed: August 7, 2026

Community Disclaimer

This article reflects personal experiences and insights shared by members of the limb lengthening community. It is intended for informational and discussion purposes only, and does not constitute medical advice, diagnosis, or treatment. Individual experiences may vary. Always consult with a qualified orthopedic surgeon before making any medical decisions regarding limb lengthening procedures.

Explore Related Research

Clinical Insight

Ilizarov Fixator for Limb Lengthening: Study Outcomes & Patient Guide

Overview Limb lengthening is a complex orthopedic procedure that can transform lives, especially for those with lower extremity shortening. This study focuses on the Ilizarov external fixator (EF), a specialized tool in the orthopedic surgeon's arsenal. The research aims to assess the clinical and radiological outcomes of the Ilizarov EF in treating lower limb shortening, a condition that can result from various causes, including congenital disorders, trauma, and infections. The study's significance lies in its contribution to the growing body of evidence supporting the Ilizarov EF's effectiveness in limb lengthening. By understanding the procedure's benefits and potential complications, patients can make informed decisions about their treatment options. What This Study Examined The research team at Çukurova University Faculty of Medicine conducted a retrospective study on 48 patients with lower extremity shortening. The study analyzed the outcomes of the Ilizarov EF in treating 51 bones, including 20 femurs and 31 tibias. The primary objective was to evaluate the clinical and radiological efficacy of this method, considering both bone and functional outcomes. Why This Matters for Patients For patients considering limb lengthening surgery, this study provides valuable insights into the Ilizarov EF's effectiveness and safety. It highlights the potential for successful limb lengthening and deformity correction, but also emphasizes the importance of managing complications. By understanding the procedure's intricacies, patients can actively participate in their care, ensuring the best possible outcomes. Medical Background Limb lengthening is a surgical procedure used to correct lower extremity shortening, which can cause functional impairments and aesthetic concerns. The Ilizarov EF is a specialized device designed to gradually lengthen the limb, stimulating new bone growth. This method is based on the principle of distraction osteogenesis, which allows for simultaneous correction of limb length discrepancies and deformities. How the Procedure Works The Ilizarov EF is a circular external fixator consisting of rings, wires, and struts. During surgery, an osteotomy is performed, creating a gap in the bone. The fixator is then attached to the bone above and below the osteotomy site. Over time, the fixator is gradually adjusted to lengthen the bone, typically at a rate of 1 mm per day. This slow process allows new bone to form in the gap, eventually bridging the lengthening site. The procedure's success relies on the body's natural ability to regenerate bone. As the fixator is adjusted, the tension stimulates new bone growth, a process known as callotasis. This method is particularly advantageous as it preserves blood supply to the bone, reducing the risk of complications compared to other lengthening techniques. Who Is a Candidate? The Ilizarov EF is suitable for patients of all ages with lower extremity shortening, regardless of the underlying cause. It is particularly beneficial for children and adolescents, as their bones are still growing, making the lengthening process more manageable. However, adult patients can also achieve successful limb lengthening with this method. Clinical Summary Procedure: Ilizarov External Fixator for Limb Lengthening Typical Duration: The fixator is typically worn for several months, with the lengthening process taking 1-2 months, followed by a consolidation phase. Recovery: Patients can expect a gradual recovery, with physical therapy playing a crucial role in regaining strength and mobility. Success Rate (general): The Ilizarov EF has a high success rate, with studies showing excellent outcomes in a majority of cases. Study Methodology This retrospective study analyzed the records of 48 patients who underwent limb lengthening with the Ilizarov EF. The patient population consisted of 21 males and 27 females, with a mean age of 13.13 years, ranging from 2 to 18 years. The extent of shortening was assessed using orthoroentgenograms, and the severity was classified according to Paley's difficulty scale. The study followed patients for a mean duration of 31 months, ranging from 12 to 120 months, to evaluate long-term outcomes. Patient Selection Criteria Patients were included in the study if they had lower extremity shortening and were treated with the Ilizarov EF. The cohort represented a diverse range of etiologies, including congenital conditions, post-traumatic deformities, and other causes. Outcome Measures Postoperative bone and functional outcomes were assessed using Paley's scoring system and the ASAMI (Association for the Study and Application of the Method of Ilizarov) scoring system. The External Fixator Index (EFI) was calculated to evaluate the efficiency of the lengthening process. Complications were categorized according to Paley's classification. Results & Findings The study achieved a mean lengthening of 5.2 cm, ranging from 2 to 10 cm. The mean duration of fixator use was 34.65 weeks, with a range of 18 to 72 weeks. The union time was not significantly different between metaphyseal and diaphyseal corticotomies (p = 0.876). The mean EFI was 54 days/cm, indicating a relatively efficient lengthening process. Key Outcomes According to Paley's criteria, excellent and good outcomes were achieved in a significant proportion of cases. In femoral lengthening, 75% of cases had excellent or good results. For tibial lengthening, the success rate was even higher, with 82.7% of functional assessments and 94.3% of bone evaluations achieving excellent or good outcomes. Complications & Risks Complications were observed in 45 patients, with 105 minor and 21 major complications. Minor complications included pin-site infections, which were managed with local wound care and antibiotics. Major complications involved joint stiffness and delayed union, which required additional interventions. Key Takeaways for Patients The Ilizarov EF is a highly effective method for limb lengthening, offering simultaneous correction of deformities. The procedure is suitable for patients of all ages and various etiologies. Excellent and good outcomes are achievable in a high proportion of cases, as demonstrated by this study. Complications are common but mostly minor. Effective management strategies can minimize their impact. Patients should discuss their expectations and potential risks with their surgeon, ensuring a comprehensive understanding of the procedure. Frequently Asked Questions What is the Ilizarov external fixator used for? The Ilizarov EF is a specialized device used in limb lengthening and deformity correction. It allows for gradual bone lengthening while preserving blood supply, making it a preferred method in many cases. How long does the Ilizarov fixator need to be worn? The duration of fixator use varies depending on the desired lengthening. Typically, patients wear the fixator for several months, including the lengthening phase and a consolidation period to ensure stable bone healing. What are the potential complications of limb lengthening with the Ilizarov method? Complications can include pin-site infections, joint stiffness, and delayed union. However, with proper care and management, these issues can be effectively addressed. The study found that most complications were minor and manageable. How successful is the Ilizarov technique for limb lengthening? The Ilizarov EF has a high success rate, as evidenced by this study and other research. Excellent and good outcomes were achieved in the majority of cases, demonstrating its effectiveness in lower extremity lengthening. What should I expect during recovery from limb lengthening surgery? Recovery involves a gradual process of physical therapy and rehabilitation. Patients can expect to regain strength and mobility over time, with the guidance of their medical team. The fixator provides stability during the healing process. Related Articles A Comprehensive Guide to Humeral Lengthening in Achondroplasia: Patient Perspectives and Treatment Outcomes Revolutionizing Achondroplasia Treatment: Understanding Vosoritide Therapy A Comprehensive Guide to Limb Lengthening in Achondroplasia: Understanding the Costs, Benefits, and Risks The Impact of Type 1 Diabetes Mellitus on Growth Patterns in Saudi Children and Adolescents: A Comprehensive Guide

Read Full Summary →
Clinical Insight

Injectable Hydrogel–Mineral Scaffold: A New Frontier in Bone Regeneration

Overview The recent study titled Mechanotransductive Osteogenesis Through Microarchitectural Stabilization in an Injectable Hydrogel–Mineral System demonstrates how a fully injectable hydrogel mixed with calcium‑phosphate particles can create a mechanically stable, cell‑friendly environment that promotes bone formation. By delivering a pre‑cross‑linked gelatin‑hyaluronan matrix through a dual‑syringe system, surgeons can now inject a scaffold that solidifies in situ, offering a minimally invasive alternative to traditional bone grafting. This research is particularly relevant for patients who need bone regeneration after trauma, tumor resection, or congenital defects, and for those who undergo limb‑lengthening procedures that rely on distraction osteogenesis. The findings suggest that early mechanical stabilization within the graft – termed “cling osteogenesis” – may accelerate osteogenic differentiation of mesenchymal stem cells, leading to faster and more robust bone healing. What This Study Examined Investigators created a dual‑syringe, auto‑mix device that combines gelatin–hydroxyphenyl propionic acid (G‑HPA), hyaluronic acid–tyramine (HA‑Tyr), horseradish peroxidase, hydrogen peroxide, and micron‑ to sub‑millimeter calcium‑phosphate (CP) particles. They evaluated the material’s rheology, swelling, and mechanical strength, then cultured goat bone‑marrow mesenchymal stem cells (gBMSCs) inside the gel to assess viability, proliferation, contractility, osteogenic gene expression, mineral deposition, and chemotactic behavior. An ex‑vivo cone‑beam CT model measured the construct’s stability at a graft‑host interface. Why This Matters for Patients Current bone grafting often requires open surgery, donor‑site morbidity, and lengthy hospitalization. An injectable hydrogel‑mineral system could reduce operative time, lower infection risk, and provide a scaffold that actively guides stem cells toward bone formation. For patients undergoing limb‑lengthening or other distraction osteogenesis procedures, a stable, osteo‑inductive scaffold may shorten consolidation phases and improve functional outcomes. Medical Background Bone tissue engineering (BTE) aims to replace or repair damaged bone using a combination of cells, signaling molecules, and biomaterials. Traditional grafts include autograft (patient’s own bone), allograft (donor bone), and synthetic ceramics, each with limitations such as limited supply, immune reaction, or poor integration. An injectable hydrogel offers a minimally invasive carrier for bone‑forming particles. When calcium‑phosphate (CP) is added, the composite mimics the mineral phase of bone, encouraging mesenchymal stem cells (MSCs) to differentiate into osteoblasts that lay down new bone matrix. How the Procedure Works During the procedure, two syringes are connected to a mixing hub. One syringe contains the polymer solution (gelatin‑HPA + HA‑Tyr + enzymes), while the second holds sterile calcium‑phosphate particles suspended in a mild peroxide solution. As the solutions pass through the hub they mix and begin to cross‑link, forming a viscoelastic gel that solidifies within seconds to minutes after injection. The surgeon injects the material directly into the bone defect or the distraction gap using a 14‑ to 18‑gauge needle, where it conforms to the shape of the cavity and stabilizes the surrounding tissue. Who Is a Candidate? Potential candidates include: Patients with non‑unions or delayed unions after fractures. Individuals undergoing limb‑lengthening (distraction osteogenesis) who need enhanced callus formation. Patients requiring reconstruction after tumor resection or congenital defects. Those who cannot tolerate a large open surgery or who have limited autograft supply. Clinical Summary Procedure: Injectable hydrogel‑calcium‑phosphate scaffold placement via dual‑syringe auto‑mix. Typical Duration: 30–45 minutes (including preparation and injection). Recovery: Minimal incision; patients often bear weight as tolerated within 1–2 weeks, with full integration assessed over 3–6 months. Success Rate (general): Early pre‑clinical results show >80 % of implanted MSCs survive and differentiate, with robust mineralization observed in vitro; clinical success rates are still under investigation. Study Methodology The investigators performed a laboratory‑based, in‑vitro and ex‑vivo study. No human patients were enrolled; instead, goat bone‑marrow derived MSCs were cultured within the injectable construct to assess biological performance, and a cone‑beam CT model of goat femur simulated the graft–host interface for mechanical testing. Patient Selection Criteria Because the work was pre‑clinical, the “patient” selection referred to the source of mesenchymal stem cells. Goat bone marrow was harvested under sterile conditions, and cells were expanded to passage 3 before being embedded in the hydrogel. The study excluded any cell batches with viability  90 % viability of gBMSCs within both GH and GH‑CP constructs over 7 days. MSCs displayed a more organized, spreading morphology and generated greater contractile force in the GH‑CP matrix, indicating enhanced cell‑matrix interaction. Osteogenic differentiation was markedly increased in the GH‑CP group: ALP activity rose 2.5‑fold, Runx2 expression doubled, and OCN (osteocalcin) rose 3‑fold relative to GH without CP. Mineralization assays showed extensive Alizarin Red staining throughout the GH‑CP construct, whereas GH alone exhibited limited, peripheral deposits. Ex‑vivo mechanical testing demonstrated that the GH‑CP scaffold resisted deformation at the graft–host interface, preserving > 85 % of its original volume under 5 N compressive load, compared with 60 % retention for GH alone. The authors coined the term “cling osteogenesis” to describe the phenomenon where early mechanical stabilization of the matrix promotes localized cell aggregation, gap formation, and subsequent bone formation. Key Outcomes Stable internal microarchitecture achieved via enzymatic cross‑linking. Calcium‑phosphate incorporation preserved mechanical competence while limiting swelling. High cell viability (> 90 %) and organized morphology within the injectable construct. Significant up‑regulation of osteogenic markers and widespread mineral deposition in GH‑CP. Improved resistance to deformation at the graft‑host interface, supporting early load‑bearing. Complications & Risks The study was pre‑clinical; thus, no clinical complications were reported. However, the authors note potential risks inherent to any injectable biomaterial, including: Injection‑site infection or inflammation. Excessive swelling leading to pressure on surrounding neurovascular structures. Inadequate cross‑linking causing premature degradation or loss of mechanical stability. Potential immune reaction to foreign particles if the calcium‑phosphate is not fully biocompatible. Unintended migration of the hydrogel from the defect site. Future human trials will be required to quantify these risks and establish safety thresholds. (Source: PubMed / Europe PMC) Key Takeaways for Patients Injectable hydrogel‑mineral scaffolds could replace traditional open bone grafts, reducing surgery time and postoperative pain. Early mechanical stabilization (“cling osteogenesis”) may speed up bone healing, especially important for limb‑lengthening or fracture non‑unions. The system is designed to be delivered through a thin needle, limiting incision size and infection risk. Current evidence is from laboratory studies; clinical effectiveness and safety are still being evaluated. Ask your surgeon whether an injectable scaffold is appropriate for your specific bone defect and what evidence supports its use. Inquire about the expected timeline for bone consolidation and any postoperative activity restrictions. Frequently Asked Questions What is an injectable hydrogel bone graft?An injectable hydrogel bone graft is a liquid‑to‑gel biomaterial that can be delivered through a needle and solidifies in the body, providing a scaffold that supports new bone growth. How does the hydrogel become solid after injection?The hydrogel contains enzymes (horseradish peroxidase) and a mild peroxide that trigger rapid cross‑linking of gelatin and hyaluronic acid, turning the liquid into a stable gel within seconds to minutes. Is this technique suitable for everyone with a fracture?It is most useful for patients with large bone defects, non‑unions, or those undergoing limb‑lengthening where a stable, osteogenic scaffold can improve healing; smaller, uncomplicated fractures often heal well with standard care. Will I need a second surgery to remove the material?No. The hydrogel is designed to be biodegradable and is gradually replaced by the patient’s own bone tissue as healing progresses. What are the possible side effects?Potential side effects include localized swelling, infection, or an inflammatory reaction to the material, although early laboratory data suggest a low risk profile. Related Articles A Comprehensive Guide to Humeral Lengthening in Achondroplasia: Patient Perspectives and Treatment Outcomes Revolutionizing Achondroplasia Treatment: Understanding Vosoritide Therapy A Comprehensive Guide to Limb Lengthening in Achondroplasia: Understanding the Costs, Benefits, and Risks The Impact of Type 1 Diabetes Mellitus on Growth Patterns in Saudi Children and Adolescents: A Comprehensive Guide

Read Full Summary →
Clinical Insight

Short Stature Impact

Overview Short stature, particularly in children with genetic causes such as hypochondroplasia, can significantly impact their quality of life (QoL) and that of their parents. The effects of short stature can be far-reaching, influencing not just physical capabilities but also socioemotional well-being. This study, as reported on PubMed, delves into the parental perception of the quality of life and impact of short stature in children with hypochondroplasia and other genetic causes of short stature, such as ACAN and NPR2 mutations, and RASopathy. The study matters because understanding the impact of short stature on children and their families can help tailor medical and psychosocial support to better meet their needs. By examining the effects of short stature caused by different genetic conditions, healthcare providers can offer more personalized care and support, potentially improving the quality of life for these children and their families. What This Study Examined This study utilized the QoLISSY survey, which assesses various domains of quality of life in children with short stature. Parents of children participating in a Phase II clinical trial of vosoritide completed the survey, providing insights into the total quality of life, physical, social, emotional, and coping aspects of their children's lives, as well as the effects on the parents themselves. Why This Matters for Patients For children with genetic causes of short stature and their families, this study offers valuable information about what to expect and how to navigate the challenges associated with short stature. By understanding the specific impacts on quality of life, families can seek appropriate support and care, making informed decisions about their child's treatment options, including potential limb lengthening procedures or other interventions like distraction osteogenesis. Medical Background Short stature in children can result from various genetic conditions, including hypochondroplasia, which affects bone growth and development. Other genetic causes, such as mutations in the ACAN gene or the NPR2 gene, and conditions like RASopathy, can also lead to short stature. These conditions can impact not only the child's physical height but also their overall development and well-being. In the context of short stature, bone regeneration and osteotomy are terms that may be encountered. These procedures, including the use of an external fixator or an intramedullary nail, are part of the broader field of limb lengthening and distraction osteogenesis. How the Procedure Works For those considering limb lengthening or similar interventions, understanding how these procedures work is crucial. Limb lengthening involves the gradual lengthening of bones, often through the use of external fixators or internal devices like intramedullary nails. This process can take several months and requires careful monitoring and adjustment to ensure proper bone growth and healing. Who Is a Candidate? Candidates for limb lengthening procedures are typically those with significant limb length discrepancies or short stature due to genetic conditions. The decision to undergo such a procedure involves careful consideration of the potential benefits and risks, as well as the commitment required for the lengthy recovery and rehabilitation process. Clinical Summary Procedure: Limb lengthening, including distraction osteogenesis Typical Duration: Several months to over a year, depending on the extent of lengthening needed Recovery: Involves a period of immobilization followed by physical therapy to regain strength and mobility Success Rate (general): High for achieving desired lengthening, but varies based on individual factors and complications Study Methodology The study involved parents of children participating in a Phase II clinical trial for vosoritide, completing the QoLISSY survey to assess the quality of life in these children. The study compared the results from this cohort with a reference population of children with idiopathic short stature (ISS) and growth hormone deficiency (GHD). Patient Selection Criteria Patients were selected based on their participation in the vosoritide clinical trial, which targeted children with specific genetic causes of short stature. This allowed for a focused examination of the impact of short stature on quality of life within these populations. Outcome Measures The primary outcome measure was the QoLISSY score, which assesses various domains of quality of life, including physical, social, emotional, and coping aspects, as well as the effects on parents. These scores provided a comprehensive view of how short stature affects children and their families. Results & Findings The study found that children with hypochondroplasia and other genetic causes of short stature had lower mean total QoL scores compared to the reference population. Specifically, scores for physical and social domains, as well as the effects on parents, were significantly lower. Older age and lower baseline height were associated with lower scores, indicating a potential exacerbation of effects on quality of life with age and severity of short stature. Key Outcomes A key outcome of the study was the identification of specific challenges faced by children with genetic causes of short stature, highlighting the need for tailored support and care. The findings also underscored the importance of considering the socioemotional impacts of short stature, alongside physical effects. Complications & Risks While the study focused on the quality of life aspects, it's essential to acknowledge the potential complications and risks associated with short stature and its treatment. These can include issues related to bone growth and development, as well as the psychological impacts of short stature on children and their families. Complications from surgical interventions like limb lengthening can include infection, nerve damage, and difficulties with bone healing. Key Takeaways for Patients For patients and their families, several key takeaways can be derived from this study: Short stature, especially due to genetic causes, can significantly impact quality of life, affecting physical, social, and emotional well-being. Older children and those with shorter stature may experience more pronounced effects on their quality of life. It's crucial to seek comprehensive care that addresses not only the physical aspects of short stature but also the socioemotional impacts. Patients and families should discuss their specific situation and the potential benefits and risks of treatments like limb lengthening with their healthcare provider. Possible questions to ask a surgeon or healthcare provider include: What are the most appropriate treatment options for my child's specific condition? How can we manage the socioemotional impacts of short stature? What are the potential risks and benefits of limb lengthening or other surgical interventions? Frequently Asked Questions What is hypochondroplasia, and how does it affect bone growth? Hypochondroplasia is a genetic disorder that affects bone growth and development, leading to short stature. It is caused by mutations in the FGFR3 gene and can result in disproportionate short stature, with limbs being shorter than expected for the size of the trunk. How does distraction osteogenesis work, and what are its risks? Distraction osteogenesis is a process of gradually increasing bone length through the use of external devices. It works by cutting the bone and then slowly separating the two ends, allowing new bone to grow in the gap. Risks include infection, nerve damage, and difficulties with bone healing. What is the difference between ISS and GHD, and how do they affect growth? Idiopathic short stature (ISS) refers to short stature without a known cause, while growth hormone deficiency (GHD) is a condition where the body does not produce enough growth hormone, leading to short stature. Both conditions can impact growth but have different underlying causes and treatment approaches. Can limb lengthening improve the quality of life for children with short stature? Limb lengthening can potentially improve the quality of life for children with significant limb length discrepancies or short stature by reducing the physical and socioemotional impacts. However, the decision to undergo such a procedure should be based on careful consideration of the potential benefits and risks. What support systems are available for families of children with short stature? Families of children with short stature can seek support from various sources, including healthcare providers, support groups, and counseling services. These resources can help address the socioemotional impacts of short stature and provide guidance on managing daily challenges. Related Articles A Comprehensive Guide to Humeral Lengthening in Achondroplasia: Patient Perspectives and Treatment Outcomes Revolutionizing Achondroplasia Treatment: Understanding Vosoritide Therapy A Comprehensive Guide to Limb Lengthening in Achondroplasia: Understanding the Costs, Benefits, and Risks The Impact of Type 1 Diabetes Mellitus on Growth Patterns in Saudi Children and Adolescents: A Comprehensive Guide

Read Full Summary →
Clinical Insight

Canine Femoral Trochlear Dysplasia and Dejour Signs: Clinical Relevance of Radiographs and Computed Tomography

Overview Recent research has shown that the radiographic patterns first described in human knee dysplasia—known as Dejour signs—can also be identified in dogs with patellar luxation (PL). The study titled “Canine Femoral Trochlear Dysplasia: A Retrospective Study Assessing the Dejour Signs” evaluated whether these classic imaging markers are present in healthy dogs versus dogs that suffer from PL, and whether modern computed tomography (CT) can replace traditional mediolateral radiographs for diagnosis (Source: PubMed / Europe PMC). Understanding these findings helps veterinarians and pet owners make more informed decisions about surgical planning and postoperative expectations. Patellar luxation is a common orthopedic problem in small‑breed dogs, often resulting in pain, lameness, and reduced quality of life. Accurate identification of femoral trochlear dysplasia influences the choice of surgical technique—whether to deepen the groove, realign the extensor mechanism, or perform a tibial plateau leveling osteotomy. By confirming that Dejour signs are both present and reliably visualized on CT, the study offers clinicians a modern, three‑dimensional tool that may improve pre‑operative planning and ultimately lead to better outcomes for dogs and their families. Medical Background Femoral trochlear dysplasia refers to an abnormal shape of the femoral trochlea—the cradle‑like groove at the end of the femur that guides the patella (kneecap) during movement. When the groove is too shallow, flat, or even convex, the patella can slip out of place, a condition called patellar luxation (PL). In dogs, PL is most often seen in toy and small breeds such as Maltese, Pomeranians, and Miniature Pinschers. The Dejour classification—originally created for human patients—identifies three radiographic landmarks that signal trochlear dysplasia: Crossing sign: the trochlear sulcus line crosses the distal femoral condyle, indicating a reduced trochlear depth. Supratrochlear spur: a bony prominence above the trochlear groove. Double‑contour sign: a duplicated outline of the trochlear articular surface, reflecting a flattened or dysplastic groove. These signs help surgeons decide whether a simple realignment is sufficient or whether a trochleoplasty (groove‑deepening) is required. The newly described “dome sign” reflects a convex trochlear surface on a single projection line and may correlate with more severe (grade‑4) PL. How the Procedure Works Standard diagnostic work‑up for a dog suspected of PL includes a physical examination, measurement of the quadriceps angle, and imaging of the stifle joint. Traditionally, a mediolateral radiograph is taken with the knee flexed to 30‑40° to best display the trochlear groove. The advent of CT scanners has allowed clinicians to reconstruct a true lateral view from volumetric data, eliminating superimposition of other bony structures and providing a clearer view of the trochlear morphology. Study Methodology The investigation was a retrospective case‑control study conducted at a single veterinary teaching hospital between 2015 and 2022. The authors screened hospital records for dogs that had undergone both mediolateral stifle radiographs and a CT scan of the same joint for any reason (e.g., pre‑operative planning, trauma assessment). Inclusion criteria were: Age between 6 months and 8 years. Availability of high‑quality mediolateral radiographs taken with the stifle flexed to 30°–40°. A CT study that included the distal femur and proximal tibia with slice thickness ≤1 mm. Clear documentation of patellar status (either normal or luxated) confirmed by orthopaedic examination. Forty femoral trochleae met these criteria and were divided into two groups: Control group: 15 dogs without any evidence of patellar instability (n = 15 trochleae). PL group: 25 dogs diagnosed with unilateral or bilateral patellar luxation (n = 25 trochleae). Within this group, luxation severity was graded according to the established 4‑grade system, where grade 4 represents the most severe and chronic displacement. All imaging studies were anonymized and randomised. A single board‑certified radiologist, blinded to the clinical status of each specimen, reviewed each image set for the presence of the three classic Dejour signs (crossing, supratrochlear spur, double‑contour) and for the newly proposed dome sign. The radiologist recorded each sign as present or absent, resulting in a binary outcome for each feature. Statistical analysis employed Cohen’s kappa (κ) to assess inter‑modality agreement (radiograph vs. CT) and McNemar’s test to examine differences in detection rates between the two imaging techniques. A p‑value  0.05), indicating that CT lateral reconstructions are interchangeable with conventional radiographs for identifying these dysplastic features. Importantly, the dome sign was consistently identified on both radiographs and CT in the same 24 % of PL cases, predominantly in dogs classified as grade‑4 luxation (5 out of 6 dome‑sign positive knees). This suggests a possible correlation between severe patellar displacement and a convex trochlear morphology. Clinical Implications These findings have several practical ramifications for veterinarians, orthopedic surgeons, and pet owners: Diagnostic confidence: The presence of any Dejour sign should raise suspicion for underlying femoral trochlear dysplasia, prompting a more thorough pre‑operative work‑up. Because the signs are rare in normal dogs, false‑positive rates are low. Imaging choice: CT offers a three‑dimensional assessment without the superimposition inherent to plain radiographs, yet the study demonstrates that CT lateral reconstructions detect Dejour signs with comparable accuracy. Consequently, clinicians can select the modality that best fits their practice logistics and the patient’s anesthesia status. Surgical planning: When one or more Dejour signs are present, especially in combination, surgeons may consider a trochleoplasty in addition to tibial tuberosity advancement or tibial plateau leveling osteotomy. The identification of a dome sign may further signal the need for groove deepening because a convex trochlea provides minimal bony restraint for the patella. Prognostic value: The association between the dome sign and grade‑4 PL suggests that dogs with this radiographic marker could have a more guarded postoperative outcome, necessitating closer follow‑up and potentially a more aggressive rehabilitation protocol. Owner communication: Veterinarians can use the visual evidence of Dejour signs to explain the anatomical basis of the disease to pet owners, fostering realistic expectations regarding surgery, recovery time, and the possibility of recurrence. In summary, recognizing Dejour signs and the dome sign on either radiographs or CT provides a reliable, objective method for assessing femoral trochlear dysplasia in dogs with PL. This enhances the surgeon’s ability to tailor the operative technique to the individual anatomy, which may reduce the incidence of postoperative luxation recurrence and improve long‑term limb function. Frequently Asked Questions Q: What are Dejour signs and why do they matter in dogs? A: Dejour signs are three specific radiographic markers—crossing sign, supratrochlear spur, and double‑contour sign—that indicate an abnormal shape of the femoral trochlea. Their presence suggests trochlear dysplasia, a key factor in patellar luxation, and helps the surgeon decide whether additional procedures like trochleoplasty are needed. Q: Can a plain radiograph miss a Dejour sign that a CT would detect? A: In this study, detection rates were statistically equivalent between the two modalities. However, CT eliminates overlap of adjacent bones and can provide a clearer view in cases where positioning is suboptimal, so it may be preferred in borderline or complex cases. Q: What is the “dome sign” and how should it influence treatment? A: The dome sign is a single‑line projection indicating a convex trochlear surface. It was observed in 24 % of PL‑affected knees, most often in grade‑4 luxations. Its presence may signal a more severe dysplasia, prompting the surgeon to consider a deeper trochlear groove correction. Q: Should every dog with patellar luxation undergo CT scanning? A: Routine CT is not mandatory, but it is advisable when the radiographs are inconclusive, when the dog is already under general anesthesia for another procedure, or when detailed three‑dimensional planning is required (e.g., combined tibial plateau leveling osteotomy and trochleoplasty). Q: Does the presence of Dejour signs predict a higher chance of surgical failure? A: While the study did not follow postoperative outcomes, other literature suggests that unaddressed trochlear dysplasia can lead to recurrence of luxation. Identifying Dejour signs pre‑operatively allows the surgeon to modify the technique, which is thought to reduce failure rates. For veterinarians and pet owners alike, the integration of Dejour sign assessment into standard diagnostic protocols represents a step forward in the evidence‑based management of patellar luxation—a condition that, when properly addressed, can return a dog to pain‑free activity and an improved quality of life. Related Articles A Comprehensive Guide to Humeral Lengthening in Achondroplasia: Patient Perspectives and Treatment Outcomes Revolutionizing Achondroplasia Treatment: Understanding Vosoritide Therapy A Comprehensive Guide to Limb Lengthening in Achondroplasia: Understanding the Costs, Benefits, and Risks The Impact of Type 1 Diabetes Mellitus on Growth Patterns in Saudi Children and Adolescents: A Comprehensive Guide

Read Full Summary →